When will keytruda patent expire?

Keytruda Patent Expiration Timeline

Pfizer's and Merck's collaboration on Keytruda (pembrolizumab), brought to market in 2014, has led to its wide adoption in treating various cancers [1]. The complex landscape of patent expiration, exclusivity, and generic availability for Keytruda has sparked considerable interest.

Original Patent Expiration Date: The original U.S. patent for pembrolizumab was granted in 2014, but various patent extensions may influence its final expiration date.

According to DrugPatentWatch.com, the U.S. patent for pembrolizumab is set to expire in 2038, after patent term extensions and exclusivity periods are accounted for [2]. It's essential to note that the patent landscape can change over time due to re-examinations, challenges, and potential lawsuits.

What Happens After Patents Expire?

After the Keytruda patent expires, generic versions of pembrolizumab may be developed and approved by the FDA. This could lead to increased competition and potentially lower costs for patients. However, developing generic versions of biologics like pembrolizumab is a complex and challenging process.

Timeline for Biosimilar Availability

Regulatory pathways for biosimilars, or generic versions of biologics, are still evolving. If approved, biosimilar versions of Keytruda might become available before the patent expires, as is the case with other biologics. However, specific timelines depend on the development, testing, and FDA approval processes.

Regulatory Environment and Future Developments

As the regulatory environment continues to evolve, it's crucial to monitor developments in the patent landscape, potential lawsuits, and FDA approvals for biosimilars and generic versions of Keytruda.

Key Sources:

1. www.merck.com (Merck & Co., INC)
2. DrugPatentWatch.com (Accessed 2023)

References:

1. Merck & Co., INC. (2023). Keytruda (pembrolizumab).
2. DrugPatentWatch.com (2023). Pembrolizumab (Keytruda) - U.S. patent expiration date.